(-)-3,7-Dimethyloct-7-enyl benzoate - CAS 10486-12-1
Category:
Main Product
Product Name:
(-)-3,7-Dimethyloct-7-enyl benzoate
Catalog Number:
10486-12-1
Synonyms:
3,7-dimethyloct-7-en-1-ylbenzoate; 10486-12-1; (-)-3,7-Dimethyloct-7-enylbenzoate; 7-Octen-1-ol,3,7-dimethyl-,benzoate,(-)-; 7-Octen-1-ol,3,7-dimethyl-,1-benzoate,(-)-; 105418-74-4
CAS Number:
10486-12-1
Molecular Weight:
260.37126;g/mol
Molecular Formula:
C17H24O2
Quantity:
Data not available, please inquire.
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC(CCCC(=C)C)CCOC(=O)C1=CC=CC=C1
InChI:
InChI=1S/C17H24O2/c1-14(2)8-7-9-15(3)12-13-19-17(18)16-10-5-4-6-11-16/h4-6,10-11,15H,1,7-9,12-13H2,2-3H3
InChIKey:
WAMANGVSGOBEEJ-UHFFFAOYSA-N
Chemical Structure
CAS 10486-12-1 (-)-3,7-Dimethyloct-7-enyl benzoate

Reference Reading


1.LC-MS/MS Analysis and Pharmacokinetics of Sodium (±)-5-Bromo-2-(α-hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-Ischemic Stroke Agent in Rats.
Tian X1,2, Liu B3, Zhang Y4, Li H5, Wei J6, Wang G7, Chang J8, Qiao H9. Molecules. 2016 Apr 16;21(4). pii: E501. doi: 10.3390/molecules21040501.
A rapid, sensitive and selective liquid chromatography-triple quadrupole mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous determination of sodium (±)-5-Bromo-2-(α-hydroxypentyl) benzoate (BZP) and its active metabolite 3-butyl-6-bromo-1(3H)-isobenzofuranone (Br-NBP) in rat plasma using potassium 2-(1-hydroxypentyl)-benzoate (PHPB) and l-3-n-butylphthalide (NBP) as internal standards (IS). Chromatographic separation was achieved on a Hypersil GOLD C18 column using a gradient elution of ammonium acetate and methanol at a flow rate of 0.2 mL/min. Good linearity was achieved within the wide concentration range of 5-10,000 ng/mL. The intra-day and inter-day precision was less than 8.71% and the accuracy was within -8.53% and 6.38% in quality control and the lower limit of quantitation samples. BZP and Br-NBP were stable during the analysis and the storage period. The method was successfully applied to pharmacokinetic studies of BZP in Sprague-Dawley rats for the first time.
2.The potential of circulating extracellular small RNAs (smexRNA) in veterinary diagnostics-Identifying biomarker signatures by multivariate data analysis.
Melanie S1, Benedikt K1, Pfaffl MW1, Irmgard R1. Biomol Detect Quantif. 2015 Sep 19;5:15-22. doi: 10.1016/j.bdq.2015.08.001. eCollection 2015.
Worldwide growth and performance-enhancing substances are used in cattle husbandry to increase productivity. In certain countries however e.g., in the EU, these practices are forbidden to prevent the consumers from potential health risks of substance residues in food. To maximize economic profit, 'black sheep' among farmers might circumvent the detection methods used in routine controls, which highlights the need for an innovative and reliable detection method. Transcriptomics is a promising new approach in the discovery of veterinary medicine biomarkers and also a missing puzzle piece, as up to date, metabolomics and proteomics are paramount. Due to increased stability and easy sampling, circulating extracellular small RNAs (smexRNAs) in bovine plasma were small RNA-sequenced and their potential to serve as biomarker candidates was evaluated using multivariate data analysis tools. After running the data evaluation pipeline, the proportion of miRNAs (microRNAs) and piRNAs (PIWI-interacting small non-coding RNAs) on the total sequenced reads was calculated.
3.Rh-Catalyzed Stereospecific Synthesis of Allenes from Propargylic Benzoates and Arylboronic Acids.
Ruchti J1, Carreira EM1. Org Lett. 2016 Apr 18. [Epub ahead of print]
An enantiospecific approach to the synthesis of optically active, trisubstituted allenes from chiral propargylic benzoates and arylboronic acids has been developed. The transformation is catalyzed by a Rh-(P,olefin) complex formed in situ from [{Rh(cod)Cl}2] and a readily available phosphoramidite ligand. The method furnishes an assortment of diverse allenes in high yields and excellent enantiospecificity under mild conditions.
4.Application of a NMR-based untargeted quantitative metabonomic approach to screen for illicit salbutamol administration in cattle.
Tang C1, Zhang K1, Liang X1, Zhao Q1, Zhang J2. Anal Bioanal Chem. 2016 Apr 26. [Epub ahead of print]
The use of metabonomic methodologies to identify illicit salbutamol administration in cattle has not been previously investigated. In this study, a nuclear magnetic resonance (NMR)-based untargeted quantitative metabonomic approach was applied to discriminate biofluid samples (plasma and urine) obtained from cattle before and after salbutamol treatment. Six male cattle (265.7 ± 3.9 kg) were fed salbutamol (0.15 mg/kg body weight) for 21 consecutive days. Plasma and urine samples were collected before and after treatment. By the use of targeted profiling, 46 and 43 metabolites in plasma and urine, respectively, were quantified, of which 9 and 11 metabolites were significantly affected (P < 0.05) by salbutamol treatment. Partial least squares discriminant analysis showed that both plasma and urine samples collected after treatment were well separated from those before treatment, with Q 2 values of 0.56 and 0.573 for plasma and urine samples, respectively.